Birth control has a broad positive impact and has expanded opportunities for women in terms of economic advancements, educational attainment, and improved health outcomes. A contraceptive helps individuals and couples to gain basic right and is a right to decide when and how many children to have. The rising adoption of traditional and modern methods of contraception has resulted in the improvement not only in health-related outcomes but in several economic and social issues. For instance, it has reduced the infant mortality and maternal mortality rates. According to Centers for Disease Control and Prevention (CDC), the introduction toward access to modern contraceptives is among one of the 10 great public health achievements of the 20th century.
The implementation of modern contraceptive methods offers safe provision by eliminating unwanted restrictive practices and medical barriers. The WHO has developed a set of medical eligibility criteria that is based on a collaborative review of all clinical, research, epidemiological, and modern contraceptive methods.
The major products in the market include:
- Yasmin and Yaz (oral pills)
- NuvaRing (Vaginal Ring)
- Milex Wide Seal (Diaphragm)
- Mirena and ParaGard (IUDs)
- Ortho Evra (or Evra patch)
- Implanon (implant)
The market is dominated by Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, and Church & Dwight, which has more than 65% to 75% market share in the Global Contraceptives Market. Factors, such as an increase in the incidence of unwanted pregnancies, rise in the adoption of oral pills and its advantages over other contraceptives, the unmet need for contraception in developing countries, growing awareness and initiatives taken by governments to prevent unwanted pregnancies, are expected to boost the market growth.
The Global Contraceptives Market is estimated to witness a CAGR of 4.3% during the forecast period 2017–2023. The market is analyzed based on three segments, namely product type, end-users, and regions.
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the contraceptives market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. The emerging markets have a high potential to grow owing to the highest proportion of young women who need to use modern contraceptives methods. Further, the government is focusing toward improvising healthcare infrastructure and creating awareness among people for early prevention of unintended pregnancies. However, the healthcare expenditure in most of the developing countries have saved millions of dollars by adopting contraceptives, especially oral pills.
The government in most of the developing countries are taking initiatives for creating awareness about contraceptives by conducting programs and collaborating with NGOs to have an effective spread of contraceptives in order to reduce poverty and illiteracy caused due to unplanned births. It is encouraging the use of condoms by supplying them door to door and imparting knowledge to prevent the spread of STDs and restrict population growth. However, few rural areas, and cultural and religious opposition in certain emerging countries, such as China, India, Thailand, Vietnam, Malaysia, and Philippines, hinder the market growth.
Contraceptive drugs are growing at a moderate rate and dominates the global contraceptives market with 62% of the total market share. Factors, such as rise in prevalence of unwanted pregnancies, rise in adoption of oral pills and its advantages over other contraceptives, and government initiatives, are driving the market growth. Contraceptive drugs are most frequently used for birth control and is widely adopted among young couples and career-oriented professional women. Contraceptive devices play an important role in saving individuals from getting STDs, preventing unwanted pregnancies, and help in family planning. The contraceptive devices market is estimated to be $10.5 billion in 2016 and is expected to reach $15.6 billion by 2023, growing at a CAGR of 5.7% during the forecast period, 2016-2023.
Allergan Plc, Bayer AG, Merck & Co., Teva Pharmaceutical, Church & Dwight, and other predominant & niche players.
The global contraceptives market has immense growth opportunities for vendors in both developed and developing regions. The market in the developed countries is seeing an increase in the adoption of modern contraceptives, especially in the US, Canada, France, Germany, the UK, and few of the Middle East countries. These countries have the highest number of frequent user population accounting to 70% to 75% of the total contraceptive population worldwide.
Pharmaceutical companies are the leading vendors in the market and have major competition with other vendors for the use of contraceptives. The market has substantial potential to gain attention of several new vendors in developing countries, thereby intensifying the competition. The vendors have strong focus on understanding the customer base by creating awareness and initiatives to generate knowledge about their products and upcoming technologically-advanced contraceptives. The growing awareness about the products and a rise in the number of physician-owned implant distributions that have resulted in an increase in the volume of contraceptive procedures have led individuals undergo implantation of contraceptive devices.
The report provides complete details about the usage and adoption rate of contraceptives for birth control, family planning, and to avoid unwanted pregnancies. Therefore, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward contraceptive adoption in the upcoming years. They can also get details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
4 Market Outlook
4.2 Porter 5 (Five) Forces
4.3 Market Segmentation
4.4 Market Dynamics
184.108.40.206 Growing incidence of unwanted pregnancies
220.127.116.11 Increase in prevalence of contraception
18.104.22.168 Rise in adoption of oral pills and its advantages over other contraceptives
22.214.171.124 Government initiatives
126.96.36.199 Unmet need for contraception in developing countries
188.8.131.52 Prolonged regulatory approvals of contraceptives
184.108.40.206 Cultural and religious opposition
220.127.116.11 Availability of low cost generic contraceptives
18.104.22.168 Limited knowledge about modern contraceptives
22.214.171.124 Intense competition among vendors
126.96.36.199 Technological advancements
188.8.131.52 Rise in effective awareness programs
184.108.40.206 High demand of cheap contraceptives
220.127.116.11 Increase in mergers and acquisition
18.104.22.168 Increase in healthcare spending
4.4.4 DRO - Impact Analysis
4.4.5 Key Stakeholders
5 Market Segmentation by Product Types: Market Size & Analysis
5.1.1 Market Size and Analysis
5.2 Contraceptive Drugs Market
5.3 Contraceptive Devices Market
5.4 Global Condom Market
5.4.1 Global IUD Market
5.4.2 Global sub-dermal Implants
5.4.3 Global Vaginal Rings Market
5.4.4 Global Non-Surgical Permanent Contraceptive Market
5.4.5 Global Diaphragms Market
5.4.6 Global Sponges Market
6 Regions: Market Size & Analysis
6.1 North America
6.1.1 Market Overview
6.2.1 Market Overview
6.3.1 Market Overview
6.4 Rest of the World
6.4.1 Market Overview
7 Competitive Landscape
7.1 Competitor Comparison Analysis
8 Vendor Profiles
8.1.1 Allergan plc
22.214.171.124 Business unit
126.96.36.199 Business focus
188.8.131.52 SWOT analysis
184.108.40.206 Business strategies
8.1.2 Bayer AG
220.127.116.11 Business unit
18.104.22.168 Business focus
22.214.171.124 SWOT analysis
126.96.36.199 Business strategies
8.1.3 Merck & Co., Inc.
188.8.131.52 Business unit
184.108.40.206 Business focus
220.127.116.11 SWOT analysis
18.104.22.168 Business strategies
8.1.4 Teva Pharmaceutical Industries Ltd
22.214.171.124 Business unit
126.96.36.199 Business focus
188.8.131.52 SWOT analysis
184.108.40.206 Business strategies
8.1.5 Church & Dwight
220.127.116.11 Business unit
18.104.22.168 Business focus
22.214.171.124 SWOT analysis
126.96.36.199 Business strategies